[Form 4] Vor Biopharma Inc. Insider Trading Activity

Rhea-AI Filing Summary

Reprogrammed Interchange LLC and Reid Hoffman reported multiple open-market sales of Vor Biopharma (VOR) common stock in September 2025. The filing discloses three non-derivative sales: 284,805 shares sold on 09/11/2025 at a weighted average price of $1.8308, 300,000 shares sold on 09/12/2025 at $1.7541, and 400,000 shares sold on 09/15/2025 at $1.6408. Following the transactions, Reprogrammed held 33,228,487 shares on a direct basis. The form clarifies the prices are weighted averages from multiple trades and states that Reid Hoffman may be deemed a beneficial owner of shares held by Reprogrammed due to shared control, but he disclaims beneficial ownership except for his pecuniary interest.

Insights

Financial Analyst

TL;DR: Significant open-market insider sales totaling 984,805 shares at sub-$2 prices; confirms liquidity-taking but not necessarily company-specific distress.

The transactions total 984,805 common shares sold across three dates in September 2025 with weighted average prices of $1.8308, $1.7541, and $1.6408. The filing provides clear quantities and prices and notes weighted-average pricing from multiple trades. Reprogrammed retains a large direct stake of 33,228,487 shares after the sales. For analysts, key metrics are the absolute share count sold and the resulting stake size; the filing contains no forward-looking statements, no derivative transactions, and no new agreements or pledges. This is a material insider disposition by a significant holder but the filing contains only factual sale details.

Corporate Governance Expert

TL;DR: Large insider disposals by an entity linked to a director may raise governance and market-sentiment questions.

The report shows coordinated sales executed by Reprogrammed Interchange LLC with signature by its manager and by Reid Hoffman. The disclosure that Mr. Hoffman "may be deemed a beneficial owner" but disclaims such ownership is important for understanding control and disclosure responsibilities. The form documents compliance with Section 16 reporting requirements and commits to providing trade-level details on request. While factual, these disposals are material from a governance perspective because they involve a director-linked entity selling nearly one million shares over a short period.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Reprogrammed Interchange LLC

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		S		284,805	D	$1.8308(1)	33,928,487(2)	D
Common Stock	09/12/2025		S		300,000	D	$1.7541(3)	33,628,487(2)	D
Common Stock	09/15/2025		S		400,000	D	$1.6408(4)	33,228,487(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Reprogrammed Interchange LLC

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Hoffman Reid

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $1.81 to $1.855. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

2. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.

3. This transaction was executed in multiple trades at prices ranging from $1.73 to $1.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $1.57 to $1.765. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Reid Hoffman	09/15/2025
	/s/ Frank Huang, Manager of Reprogrammed Interchange LLC	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Vor Biopharma (VOR) report on this Form 4?

The Form 4 reports three open-market sales totaling 984,805 shares executed on 09/11/2025 (284,805 shares), 09/12/2025 (300,000 shares), and 09/15/2025 (400,000 shares).

At what prices were the VOR shares sold in the filing?

The weighted average sale prices reported are $1.8308 (09/11/2025), $1.7541 (09/12/2025), and $1.6408 (09/15/2025); each reflects multiple trades.

Who are the reporting persons on the Form 4 for VOR?

The reporting persons are Reprogrammed Interchange LLC (address: 101 Mission Street, San Francisco) and Reid Hoffman, listed as a director and linked to Reprogrammed.

How many VOR shares does Reprogrammed hold after the reported sales?

Following the reported transactions, Reprogrammed directly held 33,228,487 shares of Vor Biopharma common stock.

Does Reid Hoffman claim beneficial ownership of the shares held by Reprogrammed?

The filing states Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed due to shared control, but he disclaims beneficial ownership except to the extent of his pecuniary interest.